Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $12.80.
Several analysts have recently issued reports on the stock. Benchmark reissued a "buy" rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. HC Wainwright raised their price objective on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. Zacks Research raised shares of Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a report on Monday, August 3rd. Finally, LADENBURG THALM/SH SH increased their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Tuesday, May 12th.
Check Out Our Latest Stock Analysis on DRTS
Insider Transactions at Alpha Tau Medical
In other Alpha Tau Medical news, CFO Raphi Levy sold 2,871 shares of the firm's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $15.00, for a total value of $43,065.00. Following the completion of the transaction, the chief financial officer owned 90,180 shares in the company, valued at $1,352,700. This trade represents a 3.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 132,871 shares of company stock worth $1,562,208. Corporate insiders own 39.50% of the company's stock.
Institutional Investors Weigh In On Alpha Tau Medical
A number of institutional investors and hedge funds have recently modified their holdings of the company. Envestnet Asset Management Inc. bought a new position in shares of Alpha Tau Medical in the third quarter valued at approximately $62,000. Bank of America Corp DE increased its holdings in Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock worth $101,000 after acquiring an additional 21,677 shares during the period. Millennium Management LLC bought a new stake in Alpha Tau Medical during the 3rd quarter worth approximately $170,000. Mariner LLC lifted its stake in Alpha Tau Medical by 185.8% in the 3rd quarter. Mariner LLC now owns 123,250 shares of the company's stock worth $556,000 after purchasing an additional 80,129 shares in the last quarter. Finally, Trifecta Capital Advisors LLC purchased a new stake in Alpha Tau Medical in the 4th quarter worth approximately $48,000. 2.65% of the stock is owned by hedge funds and other institutional investors.
Alpha Tau Medical Stock Performance
Shares of DRTS opened at $14.70 on Wednesday. Alpha Tau Medical has a fifty-two week low of $3.18 and a fifty-two week high of $15.02. The business has a 50-day moving average of $12.64 and a 200 day moving average of $9.73. The firm has a market cap of $1.33 billion, a P/E ratio of -14.13 and a beta of 1.17. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.14 million. As a group, research analysts forecast that Alpha Tau Medical will post -0.92 EPS for the current year.
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
